You came from your AI assistant. Add Equibles to it and ask about this data directly, free.
The company's filings, earnings calls and investor events, most recent first. Search and read these filings from Claude or ChatGPT with the SEC filings MCP server →
Incannex Healthcare Inc. reports that its IHL-42X Phase 2 safety and efficacy study comparing 9 doses commenced July 2026; its Phase 2/3 and bioavailability studies are completed.
Incannex Healthcare Inc.’s virtual 2026 annual meeting is December 17, 2026. Stockholders will elect Joel Latham and Troy Valentine as Class III directors through 2029 and ratify Grant Thornton Audit Pty Ltd for the fiscal year ending June 30, 2027.
Incannex Healthcare Inc. is enrolling the DReAMzz Study for IHL-42X in OSA across 14 U.S. clinical sites, with completion estimated in mid-2027. It reported a comprehensive loss of $19.8 million and cash of $68.4 million as of September 24, 2026.
